Acuta Capital Partners’s RayzeBio, Inc. Common Stock RYZB Stock Holding History

Acuta Capital Partners’s Portfolio RYZB Stock Details RYZB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-378,069	Closed	-$23.5M	–	45
2023 Q4	$23.5M	Buy	378,069 +33,498	+10%	+$833K	13.23%	1
2023 Q3	$7.65M	Buy	+344,571	New	+$7.23M	5.13%	5

Acuta Capital Partners's RYZB Position: Q1 2024 in Review

Acuta Capital Partners sold out of RayzeBio, Inc. Common Stock (RYZB) in Q1 2024, closing a stake of 378,069 shares — an estimated $23.5M sold.

Acuta Capital Partners first reported a position in RYZB in Q3 2023 and held it in 2 quarters. The position peaked at $23.5M in Q4 2023. 0 funds tracked by Wall St. Rank hold RYZB as of Q1 2024.

Acuta Capital Partners reported no remaining RayzeBio, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Acuta Capital Partners sold 378,069 RayzeBio, Inc. Common Stock shares in Q1 2024, an estimated $23.5M.
Acuta Capital Partners first reported a position in RayzeBio, Inc. Common Stock in Q3 2023 and held it in 2 quarters.
Acuta Capital Partners's RayzeBio, Inc. Common Stock position peaked at $23.5M in Q4 2023.
0 funds tracked by Wall St. Rank held RayzeBio, Inc. Common Stock as of Q1 2024.

Based on Acuta Capital Partners's 13F filing for Q1 2024, filed 15 May 2024.